SBIR/STTR Research Award

QUANTITATIVE ANALYSIS OF RH ANTIBODIES

Award identifier 2534cb7cf0b33e9b6ce5cde35b3b7533baec7d687af0f6e5c4b5ea0d444861b0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$120,004

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ALLIED INNOVATIVE SYSTEMS
Proposal award date
Not reported
Contract end date
Not reported
UEI
SFFKG8THUH55
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The objective of this proposal is to develop a quantitative ELISA assay for quantitative measurement of anti-RhD antibodies. Specific aims include isolation of soluble serologically active RhD, coating ELISA plates with the extract, enhancing the sensitivity of antibody detection using the Photochemical Amplification Method (PAM) and the Fluorescence Enhancement Technique (FET), measuring stability of extract after drying, and analyzing the IgG subclass distribution of anti- RhD antibodies. Soluble RhD extract will be coated on ELISA plates according to the patented protocols with varying concentrations of extract, ELISA assays using PAM and FET will be optimized and standard curves for quantitation of anti-RhD antibodies will be constructed with standards of known anti-RhD concentration. Studies of anti-Rh subclass distribution will be done after ELISA optimization. Successful completion of the project will provide protocols for eliminating variations in the current doubling dilution titering method by making available a strictly quantitative means of measuring anti- RhD antibodies. Measurement of anti-RhD subclasses in patient sera will provide new insight into known variations in severity of Hemolytic Disease of the Newborn. The research will create new business opportunities and will benefit patients. PROPOSED COMMERCIAL APPLICATION: This research will lead to development of protocols for producing commercial kits for quantitative ELISA measurement of anti-RhD antibodies. These kits would be used in Blood Banks and Pathology Labs for measuring anti-RhD antibody levels in pregnant women who are carrying an RhD positive fetus. Such antibodies mediate the disease Hemolytic Disease of the Fetus. ELISA measurement would standardize assays eliminating the known variation in reported results from current methods.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

21 SBIR/STTR records share this UEI (2000–2023). Reported award amounts total $10,630,804. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.